Proto Labs (PRLB) COO Michael Kenison sells 2,500 shares under trading plan

Rhea-AI Filing Summary

Proto Labs Inc. executive stock sale disclosed

Proto Labs Inc. Chief Operations Officer Michael R. Kenison reported selling 2,500 shares of common stock on February 6, 2026 at $60 per share. After this planned trade, he beneficially owns 34,526 shares of Proto Labs common stock.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Mr. Kenison adopted on August 15, 2025, which is designed to allow insiders to sell shares according to predetermined instructions.

Insider Trade Summary

Net Seller: 2,500 shares ($150,000)

Net Sell 1 txn

Insider Kenison Michael R.

Role Chief Operations Officer

Sold 2,500 shs ($150K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,500	$60.00	$150K

Holdings After Transaction: Common Stock — 34,526 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kenison Michael R.

(Last) (First) (Middle)

5540 PIONEER CREEK DRIVE

(Street)

MAPLE PLAIN MN 55359

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Proto Labs Inc [ PRLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operations Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		S(1)		2,500	D	$60	34,526	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on August 15, 2025.

Remarks:

	/s/ W. Morgan Burns, Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Proto Labs (PRLB) report for Michael R. Kenison?

Proto Labs reported that Chief Operations Officer Michael R. Kenison sold 2,500 shares of common stock. The sale occurred on February 6, 2026 at a price of $60 per share, as shown in the Form 4 filing.

How many Proto Labs (PRLB) shares does Michael R. Kenison hold after the Form 4 sale?

After the reported transaction, Michael R. Kenison beneficially owns 34,526 shares of Proto Labs common stock. This figure reflects his holdings immediately following the 2,500-share sale disclosed in the Form 4.

At what price were the Proto Labs (PRLB) shares sold in this Form 4 filing?

The Form 4 shows that 2,500 Proto Labs common shares were sold at $60 per share. This single transaction on February 6, 2026 is the only reported trade in the non-derivative securities table.

Was the Proto Labs (PRLB) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was executed under a Rule 10b5-1 trading plan. This plan was adopted by the reporting person on August 15, 2025, providing pre-established instructions for selling shares.

What position does Michael R. Kenison hold at Proto Labs (PRLB)?

Michael R. Kenison is identified as an officer of Proto Labs Inc., serving as Chief Operations Officer. He is not listed as a director or 10% owner in this Form 4 insider ownership disclosure.

Does the Proto Labs (PRLB) Form 4 report any derivative securities transactions?

No derivative securities transactions are reported in this Form 4. The derivative securities table is present but contains no entries, indicating only a common stock sale was disclosed for the reported date.